September 2, 2021Open Access Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
Key Points
Key points are not available for this paper at this time.
Abstract
Based on data from the whole INBUILD trial, nintedanib reduced the risk of events indicating ILD progression.
Flaherty et al. (Thu,) studied this question.
The natural history of progressive fibrosing interstitial lung diseases2020 · 288 citations